https://www.selleckchem.com/pr....oducts/ginkgolic-aci
Out of 380 patients in the 13 studies, 27 had inhibitor against FVII; 18 were male, 7 were female, while the sex of 2 was not stated. The majority (92%) developed a high-titer inhibitor (Bethesda Unit 5). All patients had severe FVII deficiency (FVIIC 10%), and the majority received recombinant FVII prior to inhibitor development (N 24, 89%). Among ten patients with a detected mutation, three subjects had a common non-sense (30%), and two had a deletion (20%). Inhibitor development is a relatively rare phenomenon
Like
Comment
Share
